Salvage therapy for primary central nervous system lymphoma with 90Y-Ibritumomab and Temozolomide

被引：10

作者：

Pitini, Vincenzo ^{[1
]}

Baldari, Sergio ^{[1
]}

Altavilla, Giuseppe ^{[1
]}

Arrigo, Carmela ^{[1
]}

Naro, Claudia ^{[1
]}

Perniciaro, Francesca ^{[1
]}

机构：

[1] Univ Messina, I-98125 Messina, Italy

来源：

JOURNAL OF NEURO-ONCOLOGY | 2007年 / 83卷 / 03期

关键词：

Primary Central Nervous System Lymphoma; Y-90-Ibritumomab Tiuxetan; Temozolamide; Rituximab; magnetic resonance image;

D O I：

10.1007/s11060-006-9324-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aggressive initial treatment of Primary Central Nervous System Lymphoma (PCNSL) has achieved prolonged survival and occasional cures. However, some patients do not respond to initial therapy and others relapse after an initial remission. The optimal salvage regimen is not known and many different strategies have been proposed. In this report we describe the efficacy of a combination of Y-90-Ibritumomab Tiuxetan (Zevalin) and Temozolamide as a maintenance therapy for recurrent PCNS Lymphoma in two patients that are both alive and in complete remission after 9 and 10 months respectively. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.

引用

页码：291 / 293

页数：3

共 6 条

[1] Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma [J].